You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

ORLANDO, Fla., July 22, 2020 /PRNewswire/ --Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation has announced that the application for its 'AVERSA' Trademark in relation to its abuse deterrent technology and lead product candidatehas passed the examination and third party opposition phase and the company expects to receive a notice of allowance in due time. Previously named Defent, AVERSA abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids. Nutriband's goal is to improve the safety profile of abusable transdermal drugs, specifically fentanyl, through applying its AVERSA technology and pushing to improve the safety profile of transdermal drugs in the opioid space. About Nutriband Inc. The Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. The product is combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. The Company's website iswww.nutriband.comand 4P's website iswww.4PTherapeutics.com. Any material contained in or derived from the Company's or 4P's websites or any other website is not part of this press release. About Our Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability obtain Federal Food and Drug Administration approval to market any product it may develop inthe United Statesand to obtain any other regulatory approval necessary to market any product in other countries, including countries inEurope, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized development stage company that does not have a product that can be marketed and the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for the year endedJanuary 31, 2020and under "Management's Discussion and Analysis of Financial Conditions and Results of Operations" in the Company's Form 10-Q for the three months endedApril 30, 2020, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof. For more information, contact:Victor RobertsRed Chip Companies407-571-0909[emailprotected]www.redchip.com Gerald Weigel Public Relations Principal Nutriband Inc. Nutriband Office: 407-377-6695 Direct: 419-304-6300 [emailprotected] SOURCE Nutriband Inc.

Answer: Nutriband's AVERSA Trademark Application Receives No Opposition